Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Rockland Immunochemicals Acquires Epi-Plus® Product Line

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
Rockland Immunochemicals, Inc. announced the acquisition of the Epi-Plus® antibody product line from 21st Century Biochemicals, Inc.

Epi-Plus® antibodies are widely regarded as the most well validated antibodies available for epigenetics research. All Epi-Plus® antibodies are multi-assay validated, including dot blot testing using modified peptide arrays, western blots, and chromatin immunoprecipitation (ChIP).

Current research in Epigenetics, the study of changes in gene expression or cellular phenotype, has shown that epigenetic pharmaceuticals could be a putative replacement or adjuvant therapy for currently accepted treatment methods such as radiation and chemotherapy. The global revenue market for epigenetics has been estimated at $2.6 Billion in 2012 and is expected to reach $8 Billion by 2017, a five-year CAGR of 25%.

"The acquisition of the Epi-Plus® product line expands Rockland’s Life Science Tools portfolio and will allow our customers to perform their research in a more efficient and effective manner, ultimately saving time and precious research dollars," commented Jim Fendrick, President and CEO of Rockland Immunochemicals. “The fact that the Epi-Plus® brand is co-owned by Novus Biologicals also allows us to expand the Rockland brand globally."

“As 21st Century Biochemicals continues to focus its efforts on providing US manufactured custom peptide and antibody solutions for its customers, we are pleased that the Epi-Plus® product line is a strong strategic fit for the Rockland portfolio,” added Dr. Jordan Fishman, President and CSO of 21st Century Biochemicals.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Rockland Awarded SBIR Funding
Company awarded grant to develop antibody-based point of care device for the diagnosis of sickle cell disease.
Tuesday, September 09, 2014
Rockland Immunochemicals Expands into 60,000 Square Foot Facility
Company expands laboratories to keep pace with growth.
Thursday, May 29, 2014
Rockland Immunochemicals Awarded Phase I SBIR Funding
SBIR grant to develop nanoprobes for in vivo imaging of cancer cells and tumors.
Tuesday, October 22, 2013
Rockland and LIMR Expand Licensing and Commercialization Relationship
Rockland will market established technologies including the CellCountEZ®, OxPhos™, RadDose™ and the Intracellular ThiolEZ™ assays.
Tuesday, October 30, 2012
Rockland Immunochemicals Awarded Phase II SBIR Funding
Company receives grant for 1 million dollars to develop Akt/mTOR signaling pharmacodynamics assay.
Tuesday, October 16, 2012
Rockland Immunochemicals and LDI Form Antibody Commercialization Partnership
Rockland will market LDI’s entire portfolio of LIMR monoclonal and polyclonal antibodies.
Monday, April 23, 2012
Rockland Immunochemicals and Emory University Sign Master Reagent Agreement
Rockland and Emory collaborate to develop novel antibodies and antibody based tools for cancer, cell signaling and chromatin research.
Friday, January 28, 2011
Rockland Immunochemicals Awarded Phase I Funding to Develop Generic Antibodies for the Treatment of Cancer
Rockland Immunochemicals Inc. have received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop generic antibodies “biosimilars” for the treatment of cancer.
Thursday, November 04, 2010
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
New Tool Uses 'Drug Spillover' to Match Cancer Patients with Treatments
Researchers have developed a new tool that improves the ability to match drugs to disease: the Kinase Addiction Ranker (KAR) predicts what genetics are truly driving the cancer in any population of cells and chooses the best "kinase inhibitor" to silence these dangerous genetic causes of disease.
Understanding the Molecular Origin of Epigenetic Markers
Researchers at IRB Barcelona discover the molecular mechanism that determines how epigenetic markers influence gene expression.
HIV Susceptibility Linked to Little-Understood Immune Cell Class
High levels of diversity among immune cells called natural killer cells may strongly predispose people to infection by HIV, and may be driven by prior viral exposures, according to a new study.
Diagnostic Test Developed for Enterovirus D68
researchers at Washington University School of Medicine in St. Louis have developed a diagnostic test to quickly detect enterovirus D68 (EV-D68), a respiratory virus that caused unusually severe illness in children last year.
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!